# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001144204-16-111273
Filing Date
2016-07-01
Accepted
2016-07-01 17:04:30
Documents
7
Period of Report
2016-08-07
Effectiveness Date
2016-07-01

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | v443094_def14a.htm | DEF 14A | 552660
2 | GRAPHIC | line.gif | GRAPHIC | 43
3 | GRAPHIC | logo_protalix.jpg | GRAPHIC | 25457
4 | GRAPHIC | sig_yossi-maimon.jpg | GRAPHIC | 9221
5 | GRAPHIC | spacer.gif | GRAPHIC | 43
6 | GRAPHIC | v443094_pc1.jpg | GRAPHIC | 935609
7 | GRAPHIC | v443094_pc2.jpg | GRAPHIC | 305436
| Complete submission text file | 0001144204-16-111273.txt |  | 2311408

Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 161747567
SIC: 2836 Biological Products, (No Diagnostic Substances)